ERBB3 and non-small cell lung carcinoma: Haikala et al. reported that EGFR-mutated NSCLC PDX models also demonstrated an upregulated cell membrane HER3 expression and EGFR/HER3 dimerization after treatment with EGFR-TKI osimertinib [29].